Evaluation of a nutrient starvation model ofMycobacterium tuberculosispersistence by gene and protein expression profiling
JC Betts,PTLukey, LC Robb, RA McAdam… - Molecular …, 2002 - Wiley Online Library
The search for new TB drugs that rapidly and effectively sterilize the tissues and are thus able
to shorten the duration of chemotherapy from the current 6 months has been hampered by …
to shorten the duration of chemotherapy from the current 6 months has been hampered by …
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study
…, RP Marshall,MA Karsdal,PTLukey… - The lancet Respiratory …, 2015 - Elsevier
Background Idiopathic pulmonary fibrosis, a progressive and inevitably fatal disorder, has a
highly variable clinical course. Biomarkers that reflect disease activity are urgently needed to …
highly variable clinical course. Biomarkers that reflect disease activity are urgently needed to …
Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response
…,K Ronacher, EC King,PTLukey… - The Journal of …, 2013 - academic.oup.com
Background. Accurate assessment of treatment efficacy would facilitate clinical trials of new
antituberculosis drugs. We hypothesized that early alterations in peripheral immunity could …
antituberculosis drugs. We hypothesized that early alterations in peripheral immunity could …
In Situ Detection ofMycobacterium tuberculosisTranscripts in Human Lung Granulomas Reveals Differential Gene Expression in Necrotic Lesions
…, JC Betts, P Helden,PTLukey… - Infection and …, 2002 - Am Soc Microbiol
We have used RNA-RNA in situ hybridization to detect the expression of several Mycobacterium
tuberculosis genes in tuberculous granulomas in lung tissue sections from tuberculosis …
tuberculosis genes in tuberculous granulomas in lung tissue sections from tuberculosis …
Signature Gene Expression Profiles Discriminate between Isoniazid-, Thiolactomycin-, and Triclosan-TreatedMycobacterium tuberculosis
…, MG Lennon, FM Kelly,PTLukey… - Antimicrobial agents …, 2003 - Am Soc Microbiol
Genomic technologies have the potential to greatly increase the efficiency of the drug
development process. As part of our tuberculosis drug discovery program, we used DNA …
development process. As part of our tuberculosis drug discovery program, we used DNA …
An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study
Background Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable
disease trajectory. The aim of this study was to assess potential biomarkers to predict …
disease trajectory. The aim of this study was to assess potential biomarkers to predict …
Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis
…, PD van Helden, K Duncan,PTLukey- The Journal of …, 2007 - academic.oup.com
Background. The majority of patients with tuberculosis who comply with appropriate treatment
are cured. However, ∼5% subsequently have a repeat disease episode, usually within 2 …
are cured. However, ∼5% subsequently have a repeat disease episode, usually within 2 …
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
…,AG Nicholson, AD Blanchard, RP Marshall,PTLukey… - Thorax, 2016 - thorax.bmj.com
Rationale Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal of all
fibrotic conditions with no curative therapies. Common pathomechanisms between IPF and …
fibrotic conditions with no curative therapies. Common pathomechanisms between IPF and …
Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis
Rationale: Recent clinical trial successes have created an urgent need for earlier and more
sensitive endpoints of disease progression in idiopathic pulmonary fibrosis (IPF). Domiciliary …
sensitive endpoints of disease progression in idiopathic pulmonary fibrosis (IPF). Domiciliary …
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
PTLukey, SA Harrison, S Yang, Y Man… - European …, 2019 - Eur Respiratory Soc
… Conflict of interest: PTLukeywas a GSK employee at the time of the study and is still a
shareholder. PTLukeynow works or has worked as an independent consultant to GSK R&D, the …
shareholder. PTLukeynow works or has worked as an independent consultant to GSK R&D, the …